IL-17 inhibitor

BRUSSELS, Belgium, May 19, 2026 UCB announced new Phase 3b clinical data showing that BIMZELX® (bimekizumab) demonstrated superior efficacy...

KANAGAWA, Japan, Dec. 17, 2025 — PeptiDream Inc. announced promising pre-clinical results for a novel oral dual IL-17A and...